This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Therapeutic Cocaine Vaccine: Human Laboratory Study

This study has been completed.
Information provided by (Responsible Party):
New York State Psychiatric Institute Identifier:
First received: August 24, 2009
Last updated: October 25, 2016
Last verified: October 2016

Clinical data demonstrate that a cocaine vaccine (TA-CD: Celtic Pharmaceutical) produces selective anti-cocaine antibodies, yet the impact of these antibodies on cocaine's direct effects is unknown. The objective of this human laboratory study was to measure the relationship between antibody titers and the effects of smoked cocaine on ratings of intoxication, craving and cardiovascular effects.

Cocaine-dependent volunteers not seeking drug treatment spend 2 nights per week for 13 weeks inpatient where the effects of cocaine (0, 25, 50 mg) are determined prior to vaccination and at weekly intervals thereafter. Vaccinations occur at weeks 1, 3, 5 and 9.

Condition Intervention Phase
Cocaine Dependence Biological: TA-CD Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: Tests of a Therapeutic Cocaine Vaccine

Resource links provided by NLM:

Further study details as provided by New York State Psychiatric Institute:

Primary Outcome Measures:
  • Cocaine intoxication [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Cocaine cardiovascular effects [ Time Frame: 1 year ]

Enrollment: 15
Study Start Date: March 2003
Study Completion Date: August 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Vaccine
All subjects received 4 active vaccinations with TA-CD
Biological: TA-CD
TA-CD (82,360 μg; IM) were administered at weeks 1, 3, 5 and 9.
Placebo Comparator: placebo Biological: TA-CD
TA-CD (82,360 μg; IM) were administered at weeks 1, 3, 5 and 9.

Detailed Description:
I do not desire to provide a more extensive description.

Ages Eligible for Study:   21 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Meets DSM-IV criteria for current cocaine dependence. The volunteer may meet criteria for other substance abuse, but not dependence (other than nicotine).
  2. Primary route of cocaine administration is smoking.
  3. Age 21-45.
  4. Females must be surgically sterilized or post- menopausal
  5. Able to give informed consent, and comply with study procedures.

Exclusion Criteria:

  1. Dependence on substances other than cocaine or nicotine.
  2. Judged to be noncompliant with study protocol.
  3. History of autoimmune disease, immune deficiency or hypersensitivity to other vaccines. An HIV test must be negative.
  4. Currently uses drugs intravenously
  5. Currently taking any psychotropic medication
  6. Laboratory tests that are clinically unacceptable to the study physician (BP > 140/90; BUN, creatinine, LFTs > 1.5 ULN; hematocrit < 34 for women, < 36 for men)
  7. Blood or blood products given in the three months prior to vaccination
  8. Other vaccines, including flu vaccine, given within 30 days of screening.
  9. Ongoing active infection
  10. Currently taking immunosuppressives -
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00965263

United States, New York
New York-Presbyterian Hospital
New York, New York, United States, 10032
Sponsors and Collaborators
New York State Psychiatric Institute
Principal Investigator: Margaret Haney, Ph.D. Columbia University
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: New York State Psychiatric Institute Identifier: NCT00965263     History of Changes
Other Study ID Numbers: #3980
NIDA 1U19DA10946
Study First Received: August 24, 2009
Last Updated: October 25, 2016

Keywords provided by New York State Psychiatric Institute:

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Immunologic Factors
Physiological Effects of Drugs
Anesthetics, Local
Central Nervous System Depressants
Sensory System Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents processed this record on September 25, 2017